Publikace na 2. lékařská fakulta |
2021
Abstrakt
In recent years several IBD cases in adult patients on ixekizumab therapy have been reported (4). Analysis of adverse events integrated from 7 randomized trials with ixekizumab in adult patients with psoriasis showed that IBD cases were uncommon and occurred in 40 years, which is in line with the average age of patients with psoriasis and an indication of adult psoriasis.
However, in Europe, CD onset is most prevalent in people aged 15-29 years (1). Thus, pediatric and adolescent patients may be at higher risk of developing IBD during anti-IL-17 therapy or even many months after treatment cessation.
